Our Healthcare Services
Dei Biopharma has an offtake agreement with the Gov- ernment of Uganda to manufacture the different types of drugs that the government is currently importing and to hit that target, Dei Biop- harma has established the following facilities in the project;
- The Generics section
- The Nutraceuticals section
- The Oncology/cancer drugs
- Penicillin section
- The Cephalosporins section
- Non Beta lactum section
- The Injectable facilities
- The WFI facility
- The Parentals
- The Ophthalmolic facility
We Provide Inspiring Ideas
Dei Biopharma has an offtake agreement with the Gov- ernment of Uganda to manufacture the different types of drugs that the government is currently importing and to hit that target, Dei Biopharma has established the following facilities in the project;
- The Generics section
- The Nutraceuticals section
- The Oncology/cancer drugs
- Penicillin section
- The Cephalosporins section
- Non Beta lactum section
- The Injectable facilities
- The WFI facility
- The Parentals
- The Ophthalmolic facility
Dei Biopharma Ltd has also set up the iconic YKTM GLP Biotech Laboratories that includes the following components ;-
Cancer research, QA/QC, drug discovery, Gene therapy, cell therapy, mRNA therapeutics, vaccines, biosimilars and Biologics.
The facility will, importantly, have biological facilities to manufacture biological drugs, biosimilars, cytokines, therapeutic protein, peptides and monoclonal antibodies
The above is what makes this facility so unique and is the reason, it will cost us more than $1 billion.
The Moderna facility in Kenya making only mRNA will cost $500 million, and in comparison, considering that this is just a small component of what Dei Biopharma Ltd is putting up in Uganda, is much cheaper.
The Dei Biopharma mRNA facility has capacity to produce more than one billion doses of mRNA vaccines per year and will have a turnover of USD 10 billion annually in the 10th year.